跳至主要内容
临床试验/NCT00996697
NCT00996697已完成4 期

A Proof Of Concept Study To Evaluate Tiotropium as Add-on Therapy to Inhaled Budesonide/Formoterol Combination in COPD

Brian J Lipworth1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2006年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
23
试验地点
1
主要终点
Change in trough FEV1 for tiotropium compared to placebo when added to formoterol/budesonide combination

研究概览

简要总结

Different medications are often used in combination for the condition COPD (chronic obstructive pulmonary disease). Some medicines act by opening the airways (bronchodilators) and some act as anti-inflammatories (steroids). More recently an approach of using a combination inhaler (containing a steroid and a long-acting bronchodilator) at the same time as a long acting bronchodilator of a different group of medicines (anti-cholinergics inhalers) has been used. This approach is sometimes called 'triple therapy'. Studies which have looked at these combinations usually use only standard blowing tests (spirometry) to test these medicines and focus on the effects of the medicines at their highest (peak) levels. It is some ways more relevant to study these medicines towards to end of the dose period (trough)- just before the next dose. This is when there is less medicine in the system, and differences in drug effects are more obvious. There are also more detailed breathing tests than spirometry which get a more detailed picture of the way the lungs respond to bronchodilator medicines. The investigators have studied 'triple therapy' in COPD, by measuring the effects at the end of the dosing interval (trough) using a range of detailed respiratory tests.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Current or ex-smokers
  • aged over 50years
  • FEV1/FVC ratio less than 0.7
  • FEV1 less than 60% predicted

排除标准

  • Diagnosis of asthma, ABPA or bronchiectasis
  • Recent RTI or steroid use
  • Inability to perform study procedures or to give informed consent
  • Known sensitivity to trial medications

研究组 & 干预措施

Triple therapy

Active Comparator

Symbicort and tiotropium

干预措施: Budesonide/formoterol and tiotropium (Drug)

Combination therapy

Placebo Comparator

Symbicort and placebo

干预措施: Budesonide/formoterol and placebo (Drug)

结局指标

主要结局

Change in trough FEV1 for tiotropium compared to placebo when added to formoterol/budesonide combination

时间窗: 2 weeks

次要结局

  • Change in IOS and bodyplethysmography at trough for tiotropium compared to placebo when added to formoterol/budesonide combination(2 weeks)
  • Change in spirometry, IOS and Bodyplethysmography at trough for formoterol/budesonide compared to washed-out baseline(4 weeks)

研究者

发起方
Brian J Lipworth
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Brian J Lipworth

Professor (Clinical) Airway allergy and COPD

University of Dundee

研究点 (1)

Loading locations...

相似试验